10/ 571,744

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1202txn

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS 3	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS 4	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS 5	APR 28	IMSRESEARCH reloaded with enhancements
NEWS 6	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS 7	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS 8	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS 9	JUN 06	KOREAPAT updated with 41,000 documents
NEWS 10	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS 11	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS 12	JUN 25	CA/CAplus and USPAT databases updated with IPC reclassification data
NEWS 13	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS 14	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS 15	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS 16	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS 17	JUL 28	CA/CAplus patent coverage enhanced
NEWS 18	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS 19	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 20	JUL 28	STN Viewer performance improved
NEWS 21	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS 22	AUG 13	CA/CAplus enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS 23	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS 24	AUG 15	CAplus currency for Korean patents enhanced
NEWS 25	AUG 25	CA/CAplus, CASREACT, and IFI and USPAT databases enhanced for more flexible patent number searching
NEWS 26	AUG 27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information
NEWS 27	SEP 18	Support for STN Express, Versions 6.01 and earlier, to be discontinued
NEWS 28	SEP 25	CA/CAplus current-awareness alert options enhanced

```
                  to accommodate supplemental CAS indexing of
                  exemplified prophetic substances
 NEWS 29  SEP 26  WPIDS, WPINDEX, and WPIX coverage of Chinese and
                  and Korean patents enhanced
 NEWS 30  SEP 29  IFICLS enhanced with new super search field
 NEWS 31  SEP 29  EMBASE and EMBAL enhanced with new search and
                  display fields

 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:31:33 ON 29 SEP 2008

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 13:31:44 ON 29 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   26 SEP 2008  HIGHEST RN 1053621-88-7
DICTIONARY FILE UPDATES:  26 SEP 2008  HIGHEST RN 1053621-88-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s alfuzosin
L1           5 ALFUZOSIN
```

```
=> dscan l1
DSCAN IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> d l1

L1   ANSWER 1 OF 5  REGISTRY  COPYRIGHT 2008 ACS on STN
RN   151651-05-7  REGISTRY
ED   Entered STN:  09 Dec 1993
CN   Androsta-3,5-diene-3-carboxylic acid, 17-[[(1,1-
     dimethylethyl)amino]carbonyl]-, (17β)-, mixt. with
     N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-
     2-furancarboxamide (9CI)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   2-Furancarboxamide, N-[3-[(4-amino-6,7-dimethoxy-2-
     quinazolinyl)methylamino]propyl]tetrahydro-, mixt. contg. (9CI)
OTHER NAMES:
CN   Alfuzosin-SKF 105657 mixt.
CN   Epristeride-alfuzosin mixt.
CN   N-tert-Butylandrosta-3,5-diene-17β-carboxamide-3-carboxylic
     acid-alfuzosin mixt.
FS   STEREOSEARCH
MF   C25 H37 N O3 . C19 H27 N5 O4
CI   MXS
SR   CA
LC   STN Files:   CA, CAPLUS, IMSPATENTS, IMSRESEARCH

     CM   1

     CRN  119169-78-7
     CMF  C25 H37 N O3

Absolute stereochemistry.
```




```
     CM   2

     CRN  81403-80-7
     CMF  C19 H27 N5 O4
```

10/ 571,744



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus
COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION
FULL ESTIMATED COST | 8.53 | 8.74

FILE 'CAPLUS' ENTERED AT 13:33:31 ON 29 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 29 Sep 2008 VOL 149 ISS 14
FILE LAST UPDATED: 28 Sep 2008 (20080928/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> d his

(FILE 'HOME' ENTERED AT 13:31:33 ON 29 SEP 2008)

FILE 'REGISTRY' ENTERED AT 13:31:44 ON 29 SEP 2008
L1 5 S ALFUZOSIN

FILE 'CAPLUS' ENTERED AT 13:33:31 ON 29 SEP 2008

=> s l1
L2 351 L1

=> s l2 and (acetone or ketone)
191754 ACETONE

```
        161177 KETONE
L3          14 L2 AND (ACETONE OR KETONE)

=> d l3 1- ibib abs hitstr
YOU HAVE REQUESTED DATA FROM 14 ANSWERS - CONTINUE? Y/(N):y

L3   ANSWER 1 OF 14  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:        2008:156861  CAPLUS
DOCUMENT NUMBER:         148:215075
TITLE:                   Process for preparation of alfuzosin hydrochloride
INVENTOR(S):             Upparapalli, Sampathkumar; Shanmuga, Sundaram Bharani
                         Kumar; Sharma, Hitesh Chandraprakash; Rao, Siripragada
                         Mahender
PATENT ASSIGNEE(S):      Orchid Chemicals & Pharmaceuticals Limited, India
SOURCE:                  PCT Int. Appl., 17pp.
                         CODEN: PIXXD2
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
     WO 2008015525        A2    20080207    WO 2007-IB2151         20070727
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,
             CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI,
             GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,
             KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
             MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,
             PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
             TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
             GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM
PRIORITY APPLN. INFO.:                       IN 2006-CH1335      A  20060731
                                             IN 2007-CH91        A  20070117
OTHER SOURCE(S):         CASREACT 148:215075
AB   The present invention pertains to a process for the preparation of alfuzosin
     hydrochloride from the condensation of N-(3-aminopropyl)-6,7-dimethoxy-N-
     methylquinazoline-2,4-diamine with tetrahydrofuran-2-carboxylic acid in
     presence of carbonyldiimidazole (CDI) in acetonitrile.  This invention
     also relates to a method for the purification of the key starting material for
     the preparation of alfuzosin hydrochloride, N-(3-aminopropyl)-6,7-dimethoxy-N-
     methylquinazoline-2,4-diamine, by transforming it to corresponding salt
     with an organic di-carboxylic acid in an alc. solvent, then separating and
     neutralizing the above di-carboxylic acid salt with a base to obtain the
     purified substrate.  Advantageously, the title process is safer, simpler,
     and more feasible at industrial scale as compare to previously disclosed
     process.
IT   81403-80-7P, Alfuzosin
     RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic
     preparation); PREP (Preparation); RACT (Reactant or reagent)
        (preparation of alfuzosin hydrochloride)
RN   81403-80-7  CAPLUS
CN   2-Furancarboxamide, N-[3-[(4-amino-6,7-dimethoxy-2-
     quinazolinyl)methylamino]propyl]tetrahydro-  (CA INDEX NAME)
```



IT 81403-68-1P, Alfuzosin hydrochloride
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(preparation of alfuzosin hydrochloride)
RN 81403-68-1 CAPLUS
CN 2-Furancarboxamide, N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L3 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:131779 CAPLUS
DOCUMENT NUMBER: 148:315160
TITLE: Polymorphs of alfuzosin hydrochloride
INVENTOR(S): Amarajyoti, Chaudhary Alka; Prabhakar, Kelkar Santosh; Shashi, Kanathala Rekha; Gopaldas, Gangrade Manish
PATENT ASSIGNEE(S): Cipla Ltd., India
SOURCE: Indian Pat. Appl., 33pp.
CODEN: INXXBQ
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 2006MU00614	A	20080125	IN 2006-MU614	20060419
PRIORITY APPLN. INFO.:			IN 2006-MU614	20060419

AB A polymorph of alfuzosin hydrochloride and a process for its preparation is described. The polymorph shows significant enhancement in bioavailability and tablets made from the polymorph have better hardness and improved disintegration time.
IT 81403-80-7, Alfuzosin
RL: PRP (Properties); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(polymorph of alfuzosin hydrochloride)
RN 81403-80-7 CAPLUS

CN 2-Furancarboxamide, N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro- (CA INDEX NAME)



IT 81403-68-1P
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(polymorph of alfuzosin hydrochloride)
RN 81403-68-1 CAPLUS
CN 2-Furancarboxamide, N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L3 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1482805 CAPLUS
DOCUMENT NUMBER: 148:106407
TITLE: New diazo coupling reactions for visible spectrophotometric determination of alfuzosin in pharmaceutical preparations
AUTHOR(S): Krishna, M. Vamsi; Sankar, D. Gowri
CORPORATE SOURCE: Pharmaceutical Analysis and Quality Assurance Division, University College of Pharmaceutical Sciences, Visakhapatnam, 530003, India
SOURCE: E-Journal of Chemistry (2007), 4(4), 496-501
CODEN: ECJHAO
PUBLISHER: WWW Publications
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Simple, rapid and sensitive spectrophotometric procedures were developed for the anal. of Alfuzosin hydrochloride (AFZ) in pure form as well as in pharmaceutical formulations. The methods are based on the reaction of AFZ with nitrite in acid medium to form diazonium ion, which is coupled with ethoxyethylenemaleic ester (Method A) or ethylcyanoacetate (Method B) or acetyl acetone (method C) in basic medium to form azo dyes, showing absorption maxima at 440, 465 and 490 nm resp. Beer's law is obeyed in the concentration of 4-20 μg/mL of AFZ for methods A, B and 3-15

μg/mL of AFZ for method C. The molar absorptivity and sandell's sensitivity of AFZ-ethoxyethylenemaleic ester, AFZ- ethylcyanoacetate and AFZ-acetyl acetone are 1.90 + 104, 0.022; 1.93 + 104, 0.021 and 2.67 + 104 L mole-1 cm-1, 0.015 μg cm-2 resp. The optimum reaction conditions and other anal. parameters were evaluated. The methods were successfully applied to the determination of AFZ in pharmaceutical formulations.

IT 81403-80-7, Alfuzosin
RL: ANT (Analyte); ANST (Analytical study)
(determination of alfuzosin in pharmaceuticals by spectroscopy using diazo coupling)

RN 81403-80-7 CAPLUS

CN 2-Furancarboxamide, N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:1334076 CAPLUS

DOCUMENT NUMBER: 148:11263

TITLE: Preparation of amino- and imino-alkylpiperazines having affinity for serotonergic receptors

INVENTOR(S): Leonardi, Amedeo; Motta, Gianni; Riva, Carlo; Guarneri, Luciano

PATENT ASSIGNEE(S): Recordati Ireland Limited, Ire.

SOURCE: U.S. Pat. Appl. Publ., 44pp.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 20070270436	A1	20071122	US 2007-751322		20070521
PRIORITY APPLN. INFO.:			US 2006-802738P	P	20060522

OTHER SOURCE(S): MARPAT 148:11263

GI



I



II

AB Title compds. represented by the formula I [wherein R = H, alkyl, alkoxy, etc.; R2a = H, alkyl, alkenyl, etc.; R2b = not present or H, alkyl, formyl, etc.; R3 = (cyclo)alkyl, alkenyl or alkynyl; R4 = (un)substituted (hetero)aryl; A = a bond or (CH2)n; m = 1 or 2; n = 1 or 2; or enantiomers, optical isomers, diastereomers, N-oxides, crystalline forms, hydrates and pharmaceutically acceptable salts thereof] were prepared For example, reaction of 1-[4-cyclohexyl-3-(2-fluorophenyl)-4-oxobutyl]-4-(2-methoxyphenyl)piperazine with hydroxylamine•HCl in EtOH/H2O at reflux for 6 h gave II in 97% yield. I were tested for binding affinity with 5-HT1A receptor, inhibition of serotonergic syndrome induced by 8-OH-DPAT in rats, and etc. Thus, I and their pharmaceutical compns., having affinity for serotonergic receptors, are useful for the treatment of patients with neuromuscular dysfunction of the lower urinary tract and CNS diseases and/or disorders associated with 5-HT1A receptor dysfunction.

IT 81403-80-7, Alfuzosin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy agent; preparation of amino- and imino-alkylpiperazines having affinity for serotonergic 5-HT1A receptors)

RN 81403-80-7 CAPLUS

CN 2-Furancarboxamide, N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro- (CA INDEX NAME)



L3 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:1016569 CAPLUS
DOCUMENT NUMBER: 148:503081
TITLE: Novel drug delivery system
INVENTOR(S): Nadkarni, Sunil Sadanand; Vaya, Navin; Karan, Rajesh Singh; Gupta, Vinod Kumar
PATENT ASSIGNEE(S): Torrent Pharmaceuticals Limited, India
SOURCE: Indian Pat. Appl., 80pp., Addn. of Indian Appl. No. 2004MU198.
CODEN: INXXBQ
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 2005MU01012	A	20070831	IN 2005-MU1012	20050826
PRIORITY APPLN. INFO.:			IN 2004-MU198 A0	20040220

AB A novel modified release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents. Present invention can optionally comprise addnl. another active ingredient as an immediate release form or modified release form. Present invention also relates to a process for preparing the said formulation.

IT 81403-80-7, Alfuzosin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel drug delivery system)
RN 81403-80-7 CAPLUS
CN 2-Furancarboxamide, N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro- (CA INDEX NAME)



L3 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:618312 CAPLUS
DOCUMENT NUMBER: 147:52927
TITLE: An improved and industrial process for the preparation of alfuzosin hydrochloride and its novel polymorphs
INVENTOR(S): Reddy, Manne Satyanarayana; Kumar, Muppa Kishore; Reddy, Bairy Kondal; Venkatesh, Mummadi
PATENT ASSIGNEE(S): MSN Laboratories Limited, India
SOURCE: PCT Int. Appl., 28pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007063556	A2	20070607	WO 2007-IN19	20070119

WO 2007063556 A3 20080731
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
PRIORITY APPLN. INFO.: IN 2006-CH2270 A 20061207
OTHER SOURCE(S): CASREACT 147:52927

AB An improved and industrial process for the preparation of alfuzosin hydrochloride and its novel polymorphs is claimed. Alfuzosin free base was prepared in two steps by amidation of 2-tetrahydrofuroic acid Me ester with 3-(methylamino)propylamine, followed by treatment of the resulting amide with 4-amino-2-chloro-6,7-dimethoxyquinazoline. After purification, alfuzosin free base was treated with HCl/MeOH to give the title compound An isopropanol-solvated form of alfuzosin hydrochloride was prepared by adding HCl/MeOH to alfuzosin free base, followed by addition of isopropanol.

IT 81403-68-1P, Alfuzosin hydrochloride
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(claimed compound; improved preparation of alfuzosin hydrochloride and its novel polymorphs)
RN 81403-68-1 CAPLUS
CN 2-Furancarboxamide, N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

IT 81403-80-7P, Alfuzosin
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(claimed compound; improved preparation of alfuzosin hydrochloride and its novel polymorphs)
RN 81403-80-7 CAPLUS
CN 2-Furancarboxamide, N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro- (CA INDEX NAME)



L3 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:418624 CAPLUS
DOCUMENT NUMBER: 148:403247
TITLE: Preparation of alfuzosin hydrochloride
INVENTOR(S): Reddy, Manne Satyanarayana
PATENT ASSIGNEE(S): MSN Laboratories Limited, India
SOURCE: Indian Pat. Appl., 18pp.
CODEN: INXXBQ
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 2005CH01248	A	20070216	IN 2005-CH1248	20050906

PRIORITY APPLN. INFO.: IN 2005-CH1248 20050906
OTHER SOURCE(S): CASREACT 148:403247
GI



I



II



III

AB A process for the preparation of the hydrochloride salt of title compound I was disclosed. For example, coupling of chloroquinazoline II and amine III afforded title compound I in 74% yield.

IT 81403-68-1P 81403-80-7P, Alfuzosin
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of alfuzosin hydrochloride)

RN 81403-68-1 CAPLUS
CN 2-Furancarboxamide, N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 81403-80-7 CAPLUS
CN 2-Furancarboxamide, N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro- (CA INDEX NAME)



L3 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:355279 CAPLUS
DOCUMENT NUMBER: 146:421999
TITLE: Preparation of alfuzosin
INVENTOR(S): Hu, Gaoyun; Xiang, Honglin; Xu, Liming
PATENT ASSIGNEE(S): Zhejiang Wanan Pharmaceutical Co., Ltd., Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 13pp.
CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1935806	A	20070328	CN 2006-10053462	20060919

PRIORITY APPLN. INFO.: CN 2006-10053462 20060919
OTHER SOURCE(S): CASREACT 146:421999
AB The title method comprises: (1) carrying out condensation reaction of 3-halopropylamine and 2-tetrahyrofurancarboxylic acid or 2-tetrahyrofurancarbonyl chloride in organic alkali at -10-100°C for 6-28 h to obtain N-3-chloropropyl-2-tetrahyrofuranrcarboxamide (I), (2) carrying out condensation reaction of I and methylamine in organic or inorg. alkali at -10-120°C for 3-30 h to obtain N-3-methylaminopropyl-2-tetrahyrofurancarboxamide (II), and (3) carrying out condensation reaction

of II and 2-chloro-2-amino-6,7-dimethoxyquinazoline at 0-120°C for 3-24 h to obtain the title compound

IT 81403-68-1P, Alfuzosin hydrochloride
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(preparation of alfuzosin)

RN 81403-68-1 CAPLUS

CN 2-Furancarboxamide, N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L3 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:230235 CAPLUS

DOCUMENT NUMBER: 146:258715

TITLE: Alfuzosin hydrochloride polymorphs

INVENTOR(S): Anumula, Raghupathi Reddy; Alla, Sampath; Madivada, Lokeswara Rao; Gilla, Goverdhan

PATENT ASSIGNEE(S): India

SOURCE: U.S. Pat. Appl. Publ., 18pp.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 20070049756	A1	20070301	US 2006-467951		20060829
IN 2005CH01210	A	20071005	IN 2005-CH1210		20050830
PRIORITY APPLN. INFO.:			IN 2005-CH1210	A	20050830
			US 2006-787704P	P	20060330

AB Alfuzosin hydrochloride crystalline and amorphous polymorphic forms and processes for preparing them are disclosed. Alfuzosin was dissolved in MeOH and HCl in MeOH was added to the solution and the solid was filtered to give an alfuzosin hydrochloride amorphous form.

IT 81403-68-1P, Alfuzosin hydrochloride
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(alfuzosin hydrochloride polymorphs)

RN 81403-68-1 CAPLUS

CN 2-Furancarboxamide, N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

IT 81403-80-7, Alfuzosin
RL: RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(alfuzosin hydrochloride polymorphs)
RN 81403-80-7 CAPLUS
CN 2-Furancarboxamide, N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro- (CA INDEX NAME)



L3 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:884823 CAPLUS
DOCUMENT NUMBER: 145:293084
TITLE: Processes for the preparation of alfuzosin and salts thereof and novel crystalline forms of alfuzosin
INVENTOR(S): Joshi, Narendra Shriram; Ramam, Buddhavarapu Pattabhi; Rao, Kodali Eswara; Bhirud, Shekhar Bhaskar; Pradhan, Nitin S.
PATENT ASSIGNEE(S): Glenmark Pharmaceuticals Limited, India
SOURCE: PCT Int. Appl., 58pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006090268	A2	20060831	WO 2006-IB431	20060228
WO 2006090268	A3	20061026		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,

IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

IN 2005MU00215	A	20060908	IN 2005-MU215		20050228
PRIORITY APPLN. INFO.:			IN 2005-MU215	A	20050228
			US 2005-662505P	P	20050316
			IN 2005-MU711	A	20050617
			US 2005-696743P	P	20050706

OTHER SOURCE(S): CASREACT 145:293084

GI



I

AB The present invention provides novel crystalline forms of alfuzosin (I) and alfuzosin hydrochloride and processes for their preparation Also provided are pharmaceutical compns. containing the new crystalline forms. Thus, alfuzosin was prepared by reacting N-(4-amino-6,7-dimethoxyquinazol-2-yl)-N-methyl-1,3-propanediamine with 2-tetrahydrofuroic acid.

IT 81403-80-7P, Alfuzosin
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(processes for the preparation of crystalline alfuzosin (polymorph A) and alfuzosin hydrochloride (polymorphs I and II))

RN 81403-80-7 CAPLUS

CN 2-Furancarboxamide, N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro- (CA INDEX NAME)



IT 81403-68-1P, Alfuzosin hydrochloride
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(processes for the preparation of crystalline alfuzosin (polymorph A) and alfuzosin hydrochloride (polymorphs I and II))

RN 81403-68-1 CAPLUS

CN 2-Furancarboxamide, N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L3 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:269392 CAPLUS
DOCUMENT NUMBER: 144:312110
TITLE: Process for preparation of crystalline alfuzosin base
INVENTOR(S): Reddy, Bandi Parthasaradhi; Reddy, Kura Rathnakar; Reddy, Rapolu Raji; Reddy, Dasari Muralidhara; Reddy, Matta Ramakrishna
PATENT ASSIGNEE(S): Hetero Drugs Limited, India
SOURCE: PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006030449	A1	20060323	WO 2004-IN292	20040916
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1789412	A1	20070530	EP 2004-770711	20040916
EP 1789412	B1	20080507		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
IN 2004CN02062	A	20070720	IN 2004-CN2062	20040916
AT 394395	T	20080515	AT 2004-770711	20040916
US 20070100143	A1	20070503	US 2006-571744	20060313
PRIORITY APPLN. INFO.:			WO 2004-IN292 W	20040916

AB The present invention relates to crystalline alfuzosin base and processes for preparation of the said crystalline solid. For example, alfuzosin base (HPLC purity: 97%) is added to methanol and heated to reflux to form a clear solution, the solution is cooled to 25 - 30°C and stirred for 12 h at the same temperature, the resulting solution is cooled to 10 - 15°C and stirred for 2 h, and the resulting solid is filtered, washed with methanol and dried at 50 - 60°C for 4 h to give 99.95% pure alfuzosin base.

IT 81403-68-1P 81403-80-7P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of crystalline alfuzosin base)
RN 81403-68-1 CAPLUS
CN 2-Furancarboxamide, N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 81403-80-7 CAPLUS
CN 2-Furancarboxamide, N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:49279 CAPLUS
DOCUMENT NUMBER: 139:159420
TITLE: Discrimination and selection of new potential antibacterial compounds using simple topological descriptors
AUTHOR(S): Murcia-Soler, Miguel; Perez-Gimenez, Facundo; Garcia-March, Francisco J.; Salabert-Salvador, M. Teresa; Diaz-Villanueva, Wladimiro; Medina-Casamayor, Piedad
CORPORATE SOURCE: Faculty of Pharmacy, Department of Physical Chemistry, Universitat de Valencia, Valencia, Spain
SOURCE: Journal of Molecular Graphics & Modelling (2003), 21(5), 375-390
CODEN: JMGMFI; ISSN: 1093-3263
PUBLISHER: Elsevier Science Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The aim of the work was to discriminate between antibacterial and non-antibacterial drugs by topol. methods and to select new potential

antibacterial agents from among new structures. The method used for antibacterial activity selection was a linear discriminant anal. (LDA). It is possible to obtain a QSAR interpretation of the information contained in the discriminant function. We make use of the pharmacol. distribution diagrams (PDDs) as a visualizing technique for the identification and selection of new antibacterial agents.

IT 81403-80-7, Alfuzosin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(discrimination and selection of new potential antibacterial compds. using simple topol. descriptors)

RN 81403-80-7 CAPLUS

CN 2-Furancarboxamide, N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro- (CA INDEX NAME)



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:755212 CAPLUS

DOCUMENT NUMBER: 137:279361

TITLE: Preparation of nitrosated and nitrosylated α-adrenergic receptor antagonists for the treatment of sexual dysfunction

INVENTOR(S): Garvey, David S.; Saenz De Tejada, Inigo; Gaston, Ricky D.; Khanapure, Subhash P.; Shelekhin, Tatiana E.; Wang, Tiansheng

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 61 pp., Cont.-in-part of U.S. 6,294,517.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 9

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020143007	A1	20021003	US 2002-146671	20020516
US 5932538	A	19990803	US 1996-595732	19960202
US 5994294	A	19991130	US 1996-714313	19960918
US 6294517	B1	20010925	US 1998-145143	19980901
US 20050187222	A1	20050825	US 2005-109761	20050420

PRIORITY APPLN. INFO.:

US 1996-595732	A2	19960202
US 1996-714313	A2	19960918
US 1998-145143	A2	19980901
WO 1997-US1294	A2	19970128
US 1999-387724	A1	19990901
US 2002-146671	A1	20020516

OTHER SOURCE(S): MARPAT 137:279361

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I, II, III, etc. [R1 = H, alkoxy; R2 = NMe(CH2)aNHCORc, 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl, etc.; a= 2, 3; Rc = heterocyclic, alkyl, hydroxyalkyl, etc.; D = NO, NO2, etc.; R3 = CH2N(4-MeC6H4)(3-DOC6H4), CH2Ph, 2-methoxy-1,4-benzodioxin-2-yl, etc.; D1 = H or D with the proviso that D1 must be D if there is no other D in the compound; R4 = H, D, CORd; R5 = H, C(O)ORk, etc.; Rd = H, alkyl, cycloalkyl, etc.; Rk = H, alkyl] were prepared For example, nitrosylation of thiol IV (X = H), e.g., prepared from 4-[2-(dimethylamino)ethoxy]-2-methyl-5-(methylethyl)phenyl acetate in 3-steps, with NaNO2/HCl afforded IV.HCL (X = NO) in 82% yield. Compds. I, II, III, etc., donate, transfer or release nitric oxide or elevate levels of endogenous endothelium-derived relaxing factor, and are useful for treatment of sexual dysfunctions in males and females. In erectile response of anesthetized rabbits (2.5 kg), S-nitrosoglutathione, e.g., prepared from glutathione and NaNO2/HCl, at 500 μg dosage was able to induce near maximal response relative to the standard dose of pap/phent/PGE1.

IT 81403-80-7D, Alfuzosin, nitrated or nitrosylated derivs.
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of nitrosated and nitrosylated α-adrenergic receptor antagonists for the treatment of sexual dysfunction)

RN 81403-80-7 CAPLUS

CN 2-Furancarboxamide, N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro- (CA INDEX NAME)



L3 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1995:909424 CAPLUS

DOCUMENT NUMBER: 123:314006

ORIGINAL REFERENCE NO.: 123:56295a,56298a

TITLE: Preparation of alfuzosin hydrochloride dihydrate

INVENTOR(S): Borrega, Regis; Kitamura, Satoshi

PATENT ASSIGNEE(S): Synthelabo S. A., Fr.

SOURCE: Eur. Pat. Appl., 15 pp.
CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 663398	A1	19950719	EP 1994-120539	19941223
EP 663398	B1	20000315		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE

JP 07206857	A	19950808	JP 1993-353828	19931228
AT 190614	T	20000415	AT 1994-120539	19941223
US 5545738	A	19960813	US 1994-364180	19941227

PRIORITY APPLN. INFO.: JP 1993-353828 A 19931228

AB Alfuzosin hydrochloride dihydrate, the most stable crystal-hydrate form of alfuzosin hydrochloride, is prepared by heating anhydrous alfuzosin hydrochloride in a 4:1 acetone-water solvent mixture at approx. 60° and cooling the solution until the dihydrate ppts. out. Numerous X-ray powder diffraction patterns of the various alfuzosin hydrochloride crystal hydrates are presented as well as data demonstrating the absorption of atmospheric water and the concomitant interchange of various alfuzosin hydrochloride crystal-hydrate states.

IT 81403-68-1, Alfuzosin hydrochloride
RL: PRP (Properties)
(preparation of alfuzosin hydrochloride dihydrate)

RN 81403-68-1 CAPLUS

CN 2-Furancarboxamide, N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

```
=> d his

     (FILE 'HOME' ENTERED AT 13:31:33 ON 29 SEP 2008)

     FILE 'REGISTRY' ENTERED AT 13:31:44 ON 29 SEP 2008
L1            5 S ALFUZOSIN

     FILE 'CAPLUS' ENTERED AT 13:33:31 ON 29 SEP 2008
L2          351 S L1
L3           14 S L2 AND (ACETONE OR KETONE)

=> s l2 and furoic
          3286 FUROIC
L4            3 L2 AND FUROIC

=> s l4 not l3
L5            3 L4 NOT L3

=> d l5 1- ibib abs hitstr
YOU HAVE REQUESTED DATA FROM 3 ANSWERS - CONTINUE? Y/(N):y

L5   ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:        2007:670612  CAPLUS
```

10/ 571,744

DOCUMENT NUMBER: 147:72792
TITLE: Process for the preparation of alfuzosin from N1-(4-amino-6,7-dimethoxyquinazolin-2-yl)-N1-methylpropylenediamine and a tetrahydro-2-furoic acid mixed anhydride.
INVENTOR(S): Nathani, Pankaj Kumar; Narode, Sunil Dnyaneshwar; Siddiqui, Mohammad Jaweed Mukarram
PATENT ASSIGNEE(S): Wockhardt Ltd., India
SOURCE: PCT Int. Appl., 18pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007069050	A2	20070621	WO 2006-IB3606	20061214
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
IN 2005MU01585	A	20070810	IN 2005-MU1585	20051216
IN 2006MU01388	A	20080808	IN 2006-MU1388	20060831
EP 1968970	A2	20080917	EP 2006-831709	20061214
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				

PRIORITY APPLN. INFO.:			
	IN 2005-MU1585	A	20051216
	IN 2006-MU1388	A	20060831
	WO 2006-IB3606	W	20061214

OTHER SOURCE(S): CASREACT 147:72792; MARPAT 147:72792
GI



I

AB Alfuzosin was prepared by reaction of N1-(4-amino-6,7-dimethoxyquinazolin-2-yl)-N1-methylpropylenediamine with a tetrahydro-2-furoic acid mixed anhydride (I; R = alkyl aryl, aralkyl, ester residue). Thus, tetrahydro-2-furoic acid in CH_2Cl_2 at 0-5° was treated with Et3N and Et chloroformate followed by stirring for 1 h. N1-(4-amino-6,7-dimethoxyquinazolin-2-yl)-N1-methylpropylenediamine (preparation given) in CH_2Cl_2 was added followed by stirring for 1 h to give 99.8% alfuzosin.
IT 81403-80-7P, Alfuzosin

RL: IMF (Industrial manufacture); PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation of alfuzosin from aminodimethoxyquinazolinylmethylpropylenediamine and a tetrahydrofuroic acid mixed anhydride)

RN 81403-80-7 CAPLUS

CN 2-Furancarboxamide, N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro- (CA INDEX NAME)



IT 81403-68-1P, Alfuzosin hydrochloride
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(preparation of alfuzosin from aminodimethoxyquinazolinylmethylpropylenediamine and a tetrahydrofuroic acid mixed anhydride)

RN 81403-68-1 CAPLUS

CN 2-Furancarboxamide, N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)



L5 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:412749 CAPLUS
DOCUMENT NUMBER: 148:379659
TITLE: Preparation of alfuzosin
INVENTOR(S): Sethuram, Chittor Chatambu; Bapat, Uday Rajaram; Sharma, Gain Chand
PATENT ASSIGNEE(S): Sanmar Speciality Chemicals Ltd., India
SOURCE: Indian Pat. Appl., 13pp.
CODEN: INXXBQ
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 2005CH00260	A	20070316	IN 2005-CH260	20050315

PRIORITY APPLN. INFO.: IN 2005-CH260 20050315
OTHER SOURCE(S): CASREACT 148:379659
GI



I



II

AB A process for the preparation of title compound I was disclosed. For example, dean-stark/toluene mediated coupling of amine II and tetrahydro-2-furoic acid afforded crude alfuzosin.

IT 81403-68-1P, Alfuzosin hydrochloride 81403-80-7P, Alfuzosin
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of alfuzosin)

RN 81403-68-1 CAPLUS
CN 2-Furancarboxamide, N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 81403-80-7 CAPLUS
CN 2-Furancarboxamide, N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro- (CA INDEX NAME)



L5 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:332954 CAPLUS
DOCUMENT NUMBER: 146:316935
TITLE: Process for preparation of alfuzosin via esterification of tetrahydro-2-furoic acid followed by coupling with N-methyl-1,3-propanediamine.
INVENTOR(S): Anumula, Raghupathi Reddy; Alla, Sampath; Gilla, Goverdhan; Bojja, Yakambram
PATENT ASSIGNEE(S): India
SOURCE: U.S. Pat. Appl. Publ., 11pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 20070066824	A1	20070322	US 2006-534226		20060922
IN 2005CH01347	A	20070914	IN 2005-CH1347		20050922
PRIORITY APPLN. INFO.:			IN 2005-CH1347	A	20050922
			US 2006-788758P	P	20060403

OTHER SOURCE(S): CASREACT 146:316935
AB A process for preparation of alfuzosin comprises esterification of tetrahydro-2-furoic acid followed by coupling of the unisolated ester with N-methyl-1,3-propanediamine. Thus, tetraydrofuroic acid in MeOH was treated with cat. H2SO4 and kept at 30° for 5 h. The mixture was added to another reactor and treated with MeOH and N-methyl-1,3-propanediamine followed by heating at 42° for 30 h to give 94.4% N1-methyl-N2-(2-tetrahydrofuroyl)-1,3-propanediamine. The latter was heated with 4-amino-2-chloro-6,7-dimethoxyquinazoline and alfuzosin in isoamyl alc. at 126-128° for 22 h to give after purification steps 46.29% alofuzosin of 99.94% purity.
IT 81403-80-7P, Alfuzosin
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(process for preparation of alfuzosin via esterification of tetrahydrofuroic acid followed by coupling with methylpropanediamine)
RN 81403-80-7 CAPLUS
CN 2-Furancarboxamide, N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro- (CA INDEX NAME)



IT 81403-68-1P, Alfuzosin hydrochloride
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(process for preparation of alfuzosin via esterification of tetrahydrofuroic acid followed by coupling with methylpropanediamine)
RN 81403-68-1 CAPLUS
CN 2-Furancarboxamide, N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

```
=> d his

     (FILE 'HOME' ENTERED AT 13:31:33 ON 29 SEP 2008)

     FILE 'REGISTRY' ENTERED AT 13:31:44 ON 29 SEP 2008
L1            5 S ALFUZOSIN

     FILE 'CAPLUS' ENTERED AT 13:33:31 ON 29 SEP 2008
L2          351 S L1
L3           14 S L2 AND (ACETONE OR KETONE)
L4            3 S L2 AND FUROIC
L5            3 S L4 NOT L3

=> log y
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                100.93     109.67

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                     ENTRY    SESSION
CA SUBSCRIBER PRICE                                -13.60     -13.60

STN INTERNATIONAL LOGOFF AT 13:36:10 ON 29 SEP 2008
```

10/ 571,744